Mrinalini Dey DrMiniDey
5 days 16 hours ago
Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for rosnilimab, a selective pathogenic T-cell depleter, with significant improvements in DAS28-CRP, ACR responses and CDAI LDA vs placebo in RA. @RheumNow https://t.co/IKKtakxpya
Jiha Lee JihaRheum
5 days 16 hours ago
#EULAR2026 Recommendations: Vasculitis
-Confirm diagnosis with imaging and biopsy
- Start GC early but with taper plan
- For major flare again confirm dx and restart GC
- Consider IL-6 or UPA
- MTX may be option if biologics not available
@RheumNow https://t.co/DqLZtW630y
Md Yuzaiful Md Yusof Yuz6Yusof
5 days 16 hours ago
#EULAR2026 POS1355 A cohort study in Japan identified 5-score predictors of GC-free remission in #lupusnephritis: HCQ, pulsed IV GC, Chronicity index=0, =>75% UPCR reduction by 6mo,& 12 mths CRR. Data cutoff 2024. Interested to see impact of current Combo tx from outset @RheumNow https://t.co/qmpgyEyOOV
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
At EULAR 2026, Dr Nikolaos Kougkas presented data from a unique real-world cohort built within joint dermatology–rheumatology university centers, following 394 patients with psoriasis on bDMARDs for up to 17 years. We sat down with Dr Kougkas to unpack the methodology, challenge the results, and draw out the clinical implications for everyday practice.
Aurelie Najm AurelieRheumo
6 days 12 hours ago
No big surprise here, deucravacitinib does as well without MTX
Pooled analysis of 52wk data of POETYK PSA
Same ACR20/50/70 and MDA response profiles also similar safety profiles
#POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS
The approach to the treatment of peripheral SpA has been the same for a long time. The guidelines recommend starting with NSAIDs, escalate to conventional synthetic DMARDs, typically sulfasalazine or methotrexate and reserve biologics for patients who fail those. According to a new phase 3 trial presented at EULAR 2026, there may be a different way to approach this.
Nelly ZIADE 🍀 Nellziade
6 days 13 hours ago
Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/uTxEJqbDBm
Nelly ZIADE 🍀 Nellziade
6 days 13 hours ago
Which b/tsDMARDs are effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/8mj24lAOTk
Jiha Lee JihaRheum
6 days 13 hours ago
Oral TYK2i deucravacitinib works for #PsA with OR without methotrexate. Pooled POETYK data (n=648): ACR20/50/MDA, enthesitis, dactylitis, skin responses, and PROs all comparable regardless of MTX use at wk 52. Good news for pts who can't tolerate MTX. @RheumNow #EULAR2026 POS0288
